Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ALGS
#3365
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+1.30%
Changement Mensuel
-19.10%
Evolution sur 6 mois
-28.19%
Changement Annuel
-28.19%
Clôture Précédente
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
Volume
2
Marchés
Actions des Marchés US
Soins de Santé
ALGS
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.53 M
1.58 M
1.59 M
2.9 M
6.11 M
—
Valuation ratios
Enterprise value
—
—
—
—
—
—
Price to earnings ratio
—
—
—
—
-1.9
-4.32
Price to sales ratio
—
—
—
—
46.99
87.35
Price to cash flow ratio
—
—
—
—
3.09
5.58
Price to book ratio
—
—
—
—
8.61
9.32
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.55
-0.65
-0.58
-1.87
-1.5
Return on equity %
-0.49
-0.69
-0.92
-0.95
-4.53
-3.38
Return on invested capital %
-1 521.51
-1 526.49
-1 163.95
-1 725.24
-2 679.38
-3 114.08
Gross margin %
—
—
—
100
100
400
Operating margin %
—
—
—
-840.02
-1 678.67
-7 847.54
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
-835.75
-2 470.55
-11.14 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
8.26
5.25
4.03
5.9
2.86
21.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0.07
0.05
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
4 682.15
17.65 K
69.13 K
-30.73
-12.89
-9.49
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
-15.35 K
-31.4 K
-109.54 K
52.79
9.08
48.19
Net current asset value per share
-15.76 K
-31.19 K
-116.28 K
54.89
9.92
50.61
Tangible book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
Working capital per share
-13.85 K
-25.25 K
-87.44 K
45.59
6.45
40.55
Book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
Nouvelles
Aligos Therapeutics conserve sa note d’achat chez H.C. Wainwright grâce aux progrès du pevifoscorvir
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Le cours d’Aligos Therapeutics augmente suite aux progrès de l’étude de phase 2 sur le VHB
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos annonce des progrès dans l’étude de phase 2 sur un médicament contre l’hépatite B
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos Therapeutics nomme James Hassard au poste de directeur commercial
Aligos therapeutics appoints James Hassard as chief commercial officer
Aligos Therapeutics : UBS initie une couverture avec une recommandation d’achat
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos rapporte un effet synergique de perte de poids avec l’agoniste THR-β
Aligos reports synergistic weight loss effect with THR-β agonist